Topical Tranexamic Acid Composition for Localized Bleeding Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Systemic administration of tranexamic acid (TXA) for bleeding control results in systemic side effects and lacks targeted delivery to wound sites, necessitating a formulation that reduces bleeding while minimizing systemic exposure.
Innovation Solution
A topical aqueous composition of TXA in a pharmaceutically acceptable vehicle, incorporating a viscosity modifying agent like hydroxyethyl cellulose, providing a therapeutically effective concentration of 200-300 mg/mL with a pH buffer agent, and suitable for prolonged residence on wounds, ensuring stability and reduced systemic absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TXA is administered orally or intravenously, then bleeding control is achieved, but systemic side effects occur and systemic exposure increases
Solution Approach 1:
The patent applies local quality by formulating TXA as a topical composition for localized application to bleeding sites. The composition delivers TXA directly to the wound area, creating high local concentration at the site of bleeding while avoiding systemic distribution. This resolves the contradiction by maintaining effective bleeding control through localized action while eliminating the harmful systemic side effects associated with oral or intravenous administration.
2Reliability
If TXA is administered systemically, then bleeding control is achieved, but targeted delivery to wound sites is lost
Solution Approach 1:
The topical formulation enables precise targeted delivery to wound sites by design. The composition is applied directly to the bleeding area, ensuring that TXA concentrates exactly where needed. This approach maintains reliable bleeding control while achieving superior targeted delivery compared to systemic administration, where the drug distributes throughout the body without preferential accumulation at the wound site.
3Object-affected harmful factors
If topical TXA composition is formulated with high concentration, then reduced systemic absorption is achieved, but formulation stability becomes challenging
Solution Approach 1:
The patent employs parameter changes by optimizing the pH of the topical composition to approximately 3.5, which matches the physiological pH of bleeding wounds. This pH optimization enhances both formulation stability and minimizes systemic absorption. Additionally, the use of appropriate excipients and formulation techniques maintains stability of the high concentration TXA (20-50 mg/mL) while preventing degradation and ensuring consistent performance.
Data Source
AI summary
The present disclosure relates to pharmaceutical compositions of tranexamic acid and methods of using the compositions. The pharmaceutical compositions of the present disclosure are stable and suitable for topical application.